Thyroid-Like Ophthalmopathy in a Euthyroid Patient Receiving Ipilimumab

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Orbit

• Publication date

  2014-10-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.3109/01676830.2014.949792PMID 25207976
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution.

  2014influential reference
• Drug-induced graves disease from CTLA-4 receptor suppression.

  2011influential reference
• [Orbital myositis associated with ipilimumab].

  2011cited by this paper
• Intubation of the Ostium and Nasolacrimal Duct With a Single Self-Linking Silicone Stent in External Dacryocystorhinostomy

  2011cited by this paper
• Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy.

  2011cited by this paper
• Graves' ophthalmopathy.

  2010cited by this paper
• Improved survival with ipilimumab in patients with metastatic melanoma.

  2010influential reference
• A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma

  2009cited by this paper
• Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

  2009cited by this paper
• Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

  2007cited by this paper
• Susceptibility genes in Graves’ ophthalmopathy: searching for a needle in a haystack?

  2007cited by this paper
• CTLA4 polymorphisms and ophthalmopathy in Graves' disease patients: association study and meta-analysis.

  2006cited by this paper
• Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4.

  2005cited by this paper
• Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer.

  2005cited by this paper
• CTLA-4 and its role in autoimmune thyroid disease.

  2003cited by this paper
• CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy.

  2001cited by this paper
• Cytotoxic T lymphocyte antigen-4 (CTLA-4) gene polymorphism confers susceptibility to thyroid associated orbitopathy.

  1999cited by this paper
• Graves' ophthalmopathy.

  1992cited by this paper

• Thyroid Eye Disease-Like Conditions Associated With Cancer and Immune Check Point Blockage: Systematic Literature Review and Case Report.

  2026cites this paper
• Neuro-Ophthalmic Complications of Immune Checkpoint Inhibitors

  2026cites this paper
• Medication-associated thyroid eye disease: a review.

  2026cites this paper
• Case Report: Development of severe inflammatory orbitopathy after immune checkpoint inhibitor initiation

  2025cites this paper
• Development of Thyrotoxicosis With Positive TSH Receptor Antibody and Transition to Hypothyroidism in a Patient With Unresectable Hepatocellular Carcinoma During Combined Atezolizumab and Bevacizumab Therapy: A Case Report and Review of the Literature.

  2025cites this paper
• New-Onset Graves’ Ophthalmopathy After Treatment with Pembrolizumab: A Case Report and a Review of the Literature

  2025cites this paper
• Association between clinical activity score and serum sPD-1 and sPD-L1 levels during systemic glucocorticoid treatment for active moderate-to-severe thyroid eye disease.

  2025cites this paper
• Ophthalmologic toxicities of antineoplastic agents in genitourinary cancers: Mechanisms, management, and clinical implications.

  2024cites this paper
• Management Aspects of Medical Therapy in Graves Disease

  2024cites this paper
• Emerging Ocular Side Effects of Immune Checkpoint Inhibitors: A Comprehensive Review

  2024cites this paper
• Immune Checkpoints and Graves' Disease, Thyroid Eye Disease, and Orbital Myopathy: A Comprehensive Review

  2024cites this paper
• Checkpoint inhibitor-related myasthenia-myocarditis-myositis overlap syndrome in the orbit

  2024cites this paper
• Immune checkpoints: new insights into the pathogenesis of thyroid eye disease

  2024cites this paper
• Update on Neuro-ophthalmic Manifestations of Immune Checkpoint Inhibitors

  2024cites this paper
• Immunological Processes in the Orbit and Indications for Current and Potential Drug Targets

  2023cites this paper
• Life-Threatening Endocrinological Immune-Related Adverse Events of Immune Checkpoint Inhibitor Therapy

  2023cites this paper
• Immune checkpoint inhibitor-related thyroid dysfunction.

  2023cites this paper
• Ocular adverse events associated with immune checkpoint inhibitors, a scoping review

  2023cites this paper
• Potential Ophthalmological Side Effects Induced by Anti-Neoplastic Regimens for the Treatment of Genitourinary Cancers: A Review

  2022cites this paper
• Immune checkpoint inhibitor-associated ophthalmic adverse events: current understanding of its mechanisms, diagnosis, and management.

  2022cites this paper
• Ocular Inflammation Induced by Immune Checkpoint Inhibitors

  2022cites this paper
• Thyroid-related adverse events induced by immune checkpoint inhibitors

  2022cites this paper
• Emerging Trends in Radionuclide Imaging of Infection and Inflammation in Pediatrics: Focus on FDG PET/CT and Immune Reactivity.

  2022cites this paper
• Durvalumab-induced thyroiditis in a patient with non-small cell lung carcinoma: a case report and review of pathogenic mechanisms

  2022cites this paper
• Ocular side effects of checkpoint inhibitors.

  2021cites this paper
• Bilateral Paraneoplastic Orbital Myositis Associated With Malignant Melanoma and Multiple Myeloma.

  2021cites this paper
• Neurologic Adverse Events of Immune Checkpoint Inhibitors

  2021cites this paper
• Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)

  2021cites this paper
• The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries

  2021cites this paper
• Oncolytic Drugs

  2021cites this paper
• Ocular adverse events in PD-1 and PD-L1 inhibitors

  2021cites this paper
• Considerations for Use of Immune Checkpoint Inhibitors in Cancer Therapy for Patients with Co-Existing Thyroid Eye Disease

  2020cites this paper
• Population-based frequency of ophthalmic adverse events in melanoma, other cancers, and after immune checkpoint inhibitor treatment.

  2020cites this paper
• Ophthalmic immune-related adverse events following anti-CTLA-4 or PD-1 therapy recorded in the American Academy of Ophthalmology IRIS® Registry.

  2020cites this paper
• Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review

  2020cites this paper
• Orbital Myositis: A Comprehensive Review and Reclassification

  2020cites this paper
• Neuro-ophthalmic Complications of Immune Checkpoint Inhibitors: A Systematic Review

  2020cites this paper
• Neuro-Ophthalmic Complications in Patients Treated With CTLA-4 and PD-1/PD-L1 Checkpoint Blockade

  2020cites this paper
• SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019)

  2020cites this paper
• Endocrine adverse events related with immune checkpoint inhibitors: an update for clinicians.

  2020cites this paper
• Ocular side effects of target therapy and immunotherapy in patients with cutaneous malignant melanoma

  2020cites this paper
• Extraocular Muscle Enlargement and Thyroid Eye Disease-like Orbital Inflammation Associated with Immune Checkpoint Inhibitor Therapy in Cancer Patients.

  2019cites this paper
• Graves’ Disease Induced by Immune Checkpoint Inhibitors: A Case Report and Review of the Literature

  2019cites this paper
• Immune checkpoint inhibitors: what neuro-ophthalmologists need to know.

  2019cites this paper
• Myositis and neuromuscular side-effects induced by immune checkpoint inhibitors.

  2019cites this paper
• [Thyroid dysfunctions secondary to cancer immunotherapy].

  2019cites this paper
• Clinical Ophthalmic Oncology

  2019cites this paper
• Orbital Disease in Neuro-Ophthalmology

  2019cites this paper
• Ocular Complications of Targeted Therapy

  2019cites this paper
• Neoplasia and intraocular inflammation: From masquerade syndromes to immunotherapy-induced uveitis.

  2019cites this paper
• Immunotherapy-induced endocrinopathies: assessment, management and monitoring

  2019cites this paper
• Drugs and Other Substances Interfering with Thyroid Function

  2018cites this paper
• Severe Inflammatory Ophthalmopathy in a Euthyroid Patient during Nivolumab Treatment

  2018cites this paper
• A case of Graves' ophthalmopathy associated with pembrolizumab (Keytruda) therapy.

  2018cites this paper
• Development of Bell's Palsy After Treatment With Ipilimumab and Nivolumab for Metastatic Melanoma: A Case Report.

  2018cites this paper
• CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects

  2018cites this paper
• Complete ophthalmoplegia in Ipilmumab and Nivolumab combination treatment for metastatic melanoma

  2018influential citation
• Thyroid eye disease: what is new to know?

  2018cites this paper
• Expert opinion on thyroid complications in immunotherapy.

  2018cites this paper
• Long-term adverse event: inflammatory orbitopathy induced by pembrolizumab in a patient with metastatic melanoma

  2018cites this paper
• French Endocrine Society Guidance on endocrine side effects of immunotherapy

  2018cites this paper
• Rapid Development of Graves' Ophthalmopathy After Treatment With Ipilimumab and Recurrence With Pembrolizumab in a Patient With Previously Treated Graves' Disease.

  2018cites this paper
• Lenalidomide-Associated Thyroid-Related Eyelid Retraction.

  2017cites this paper
• Combined immune checkpoint blockade (anti-PD-1/anti-CTLA-4): Evaluation and management of adverse drug reactions.

  2017cites this paper
• Inflammatory Orbitopathy Associated With Ipilimumab.

  2017cites this paper
• Tremelimumab-Induced Graves Hyperthyroidism


  2017cites this paper
• Molecularly targeted agents in oculoplastic surgery

  2017cites this paper
• Cancer Therapy with Checkpoint Inhibitors: Establishing a Role for Ophthalmology.

  2017cites this paper
• Endocrine side effects of cancer immunotherapy.

  2017cites this paper
• Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma

  2016cites this paper
• Nebenwirkungsmanagement bei Immun‐Checkpoint‐Blockade durch CTLA‐4‐ und PD1‐Antikörper beim metastasierten Melanom

  2016cites this paper
• Therapie bei malignen Lidtumoren

  2016cites this paper
• Management of Immunotherapy Related Adverse Effects

  2016cites this paper
• Sneaky side effects and ineffectiveness of an immunotherapy with ipilimumab in a case of metastatic melanoma

  2016cites this paper
• Immune checkpoint inhibitor‐related hypophysitis and endocrine dysfunction: clinical review

  2016cites this paper
• [Therapy options for malignant eyelid tumors].

  2016cites this paper
• Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.

  2016cites this paper
• Regulatory lymphocytes in thyroid orbitopathy and autoimmune thyroid diseases.

  2016cites this paper
• Thyroid-Induced Toxicity of Check-Point Inhibitors Immunotherapy in the Treatment of Advanced Non-Small Cell Lung Cancer

  2016influential citation
• Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper.

  2016cites this paper
• Ocular and orbital side-effects of checkpoint inhibitors: a review article

  2016cites this paper
• Management of side effects of immune checkpoint blockade by anti‐CTLA‐4 and anti‐PD‐1 antibodies in metastatic melanoma

  2016cites this paper
• Acute visual loss after ipilimumab treatment for metastatic melanoma

  2016cites this paper
• Treatment of Ipilimumab Induced Graves' Disease in a Patient with Metastatic Melanoma

  2016cites this paper
• Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.

  2015cites this paper
• Immune-mediated Adverse Effects of Anti-CTLA-4 Antibody Therapy in Metastatic Melanoma

  2015cites this paper
• Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis

  2015cites this paper
• Ipilimumab in melanoma

  2012cites this paper